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ABSTRACT:   A follow-up assessment plan after radical treatment is a part of a comprehensive approach to treating patients with breast can-
cer. Because breast cancer is the most frequent cancer both worldwide and in Poland, adequate follow-up is important not only 
for patients but also for economic reasons. 
  Herein, we review current recommendations for follow-up assessments in patients with breast cancer. The main aim of such as-
sessment is detection of early recurrence or tumor presence in the other breast, observation of long-term treatment complica-
tions, and creation of multidisciplinary infrastructure that will allow to reduce the risk of recurrence and alleviate physical, men-
tal, and social consequences of treatment. 
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In 2010, the American Society of Clinical Oncology (ASCO) 
published a list of the five most important and expensive prac-
tices in oncology (the so-called Top Five) that are used com-
monly despite the lack of evidence for their health-related 
benefits (1,2). One of those practices was lack of compliance 
with the principles of follow-up assessments in patients with 
breast cancer. 
A survey conducted among USA-based oncologists showed 
that 20-40% of them order additional studies that are not part 
of standard assessment (3-5). In Poland, despite the lack of such 
data, one can assume that the situation is similar. Responsibil-
ity for follow-up assessments should be assumed by the treat-
ing center, and in the Polish healthcare system it is shared by 
oncological and surgical institutions. 
Breast cancer, being the most common cancer both worldwide 
and in Poland, constitutes a significant social issue. An increas-
ing morbidity with constant mortality for several years (6) re-
flects the fact that breast cancer is treated successfully. Current-
ly, the five-year survival rate in the USA and Western Europe 
is estimated at 85%, and the ten-year survival rate at 70% (7,8). 
In Poland, these figures are lower by 10% (7), and tumor stage 
at diagnosis remains the most important prognostic factor. To-
tal recurrence risk for patients who receive radical treatment is 
10% (9), with 80% of all recurrence cases seen within 5 years of 
treatment, especially in the second year after diagnosis (10). It 
should be emphasized that it is not always clear if we deal with 
recurrence of a previously removed tumor or with a new tumor 
in the same breast.  One thing that is peculiar to breast cancer 
is late local or systemic recurrence, after 10-20 years since di-
agnosis, which is observed in tumors positive for estrogen or 
progesterone receptors. 
For that reason, follow-up assessments after radical treatment 
should be conducted throughout lifespan with an aim to early 
detect local recurrence and/or new tumor in the same or oth-
er breast. It is also important to assess for long-term compli-
cations of treatment, such as premature menopause, osteopo-
rosis, secondary tumors, or cardiovascular diseases. During 
follow-up, further use of hormonal treatment should encour-
age, as with time, fear of cancer decreases and with it the mo-
tivation to use long-term treatment. Periodic follow-up visits 
should also include psychological and social counselling, which 
help in full recovery (11). Data acquired during follow-up vis-
its can, in turn, be used for evaluating treatment outcomes in 
individual centers. 
Based on current knowledge, the plan of follow-up assessments 
in women with breast cancer is dependent on the stage of the 
disease. In patients after palliative treatment, it is closely asso-
Tab. I. Evidence-based ranking of recommendations in clinical guidelines (13)
LEVEL OF MEDICAL EVIDENCE  
I Evidence from at least one, large, randomized, controlled clinical trial or meta-analysis of homogenous randomized trials 
II Evidence from small, randomized trials or meta-analysis of heterogeneous randomized trials 
III Evidence from prospective cohort studies  
IV Evidence from retrospective cohort studies or case-control studies 
V Evidence from trials without control groups, descriptive studies, expert opinions 
STRENGTH OF RECOMMENDATION 
A Strong recommendation, evidence for a significant clinical benefit 
B Strong recommendation but with lower certainty, probably true for most individual cases 
C
Moderate recommendation, can be changed based on more reliable 
data; probably true, insufficient evidence for clinical efficacy, 
facultative recommendation 
D Weak evidence against clinical benefit; in principle, not recommended 
E Strong recommendation; evidence for lack of clinical efficacy; not recommended in any case  
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who have been treated with adjuvant tamoxifen, gynecological 
examination should include transvaginal US because of an in-
creased risk of endometrial cancer [V,A]. Only in patients with 
removed uteri can examination intervals be extended. 
During treatment with aromatase inhibitors, periodic assess-
ment of bone density is recommended along with supplementa-
tion of calcium and vitamin D3 [I,A]. One should pay attention 
to the increased risk of osteopenia in women over 65 years of 
age, smokers, patients with BMI below 18, alcohol abusers, and 
people with low physical activity. Current ASCO guidelines also 
recommend performing densitometry in patients who receive 
adjuvant treatment with tamoxifen and/or GnRH analogs and 
those who experience premature menopause due to chemother-
apy. The time interval between studies should be 1-2 years and 
is determined based on individual osteopenia risk (12). Because 
of potential adverse effects of hormonal therapy, patients who 
receive that treatment should be assessed for blood lipids {V,B]. 
According to ESMO guidelines, hormone replacement therapy 
is contraindicated as estrogen and progesterone significantly 
increase the risk of recurrence [I,A] (19). The most important 
elements of follow-up assessments in patients with breast can-
cer after radical treatment are summarized in Table II. 
In asymptomatic patients, routine performance of additional 
laboratory or imaging studies is not indicated for seeking out 
distal metastases [I,A]. Measurement of cancer markers (CA15.3, 
CA27.29, CEA, CA-125, MUC-1), chest x-rays, abdominal ul-
trasound, bone scintigraphy, computed tomography, magnetic 
resonance imaging, or PET are spurious. Based on a multitude 
of studies, an earlier detection of systemic recurrence owing 
to an extended follow-up assessment does not influence treat-
ment outcomes, survival, or quality of life (20-24). 
Restrictions regarding the number of studies during oncological 
follow-up pertain only to asymptomatic patients. Obviously, if 
abnormal symptoms or sings are present, the necessary diag-
nostic workup should be ordered (11). 
Perhaps, the program of follow-up assessments in patients af-
ter radical treatment of breast cancer will be changed; for in-
stance, there might be different recommendations for patients 
with different molecular subtypes of cancer. In patients with 
breast cancers that have unfavorable prognosis, assessments 
with the use of modern imaging techniques such as PET-CT or 
PET-MRI could contribute to better outcomes. New prognostic 
ciated with treatment outcomes and should be tailored to indi-
vidual patients. In the case of patients after radical treatment, 
international recommendations are available; for instance, the 
2015 recommendations of the  American Society of Clinical 
Oncology (ASCO) and European Society for Medical Oncolo-
gy (ESMO) (11,12).
Repeated and detailed physical examination is the basis for 
follow-up assessment. During the first 2 years after diagno-
sis, it should be conducted every 3-4 months; every 6 months 
for the subsequent 3 years, and every 12 months after 5 years 
since diagnosis (strength of recommendation V,A –  Tab. I] (11). 
According to ASCO, more frequent follow-up visits should be 
conducted during the first 3 years, and then they should be per-
formed every 6 months (12). 
During a follow-up visit, patients should be encouraged to 
perform systematic, monthly self-examinations and learn the 
symptoms of recurrence. In that respect, it is important to in-
form patients of the genetic aspects of the disease, and order 
additional tests if necessary. Genetic testing and genetic coun-
selling are recommended in the following situations: ovarian 
cancer in the patient or their first-order and second-order rel-
atives, breast cancer before 50 years of age in one first-order 
relative or at least two cases in first-order or second-order rel-
atives regardless of age at diagnosis, bilateral breast cancer in a 
family relative or breast cancer in a man (11). According to the 
recommendations issued by ASCO, genetic studies should also 
be performed in all patients with triple-negative breast cancer 
diagnosed before 60 years of age (12). 
Recently, promotion of a healthy lifestyle, including physical 
activity, has become an important aspect of cancer surveillance 
[II,B], and in obese women dietary counselling is recommend-
ed to attain normal weight [III,B] (14,15). 
Patients should have unlimited access to physical therapy and 
other services that alleviate physical, psychological, and social 
consequences of breast cancer. The main aim of physical ther-
apy, which has been extensively popularized, is prophylaxis of 
lymphatic edema, restoration of full motor function of the up-
per extremity, and correction of posture abnormalities that are 
seen after mastectomy. 
During oncological follow-up, mammography should be per-
formed once a year [II,A], and in patients who have been treat-
ed with breast-conserving therapy, first mammography should 
be performed 6 months after completion of radiation therapy. 
The recommendations of ASCO do not deal with routine use 
of ultrasound (US) examinations of the breasts, but ESMO rec-
ommends US assessments every 12 months [II,A], especially in 
the case of lobular cancer (11). 
Magnetic resonance imaging (MRI) is not routinely recommend-
ed; however, it can be used in young women, patients with the 
so-called dense breasts, patients with BRCA1/2 or TP53  mu-
tations (16,17), or patients after reconstructive surgery. Also, 
MRI is the study of choice for loss of implant integrality (18). 
An annual gynecological examination should also be an integral 
part of oncological follow-up. In patients with preserved uterus 
Tab. II. Basic elements of follow-up for women after radical breast cancer treatment 
Recommended study Frequency 
Brest self-exam (BSE) Every month 
Physical examination 
first 2-3 years -  every 3-4 months  
3-5 years - every 6 months 
>5 years -  every 12 months 
Mammography and breast US every 12 months 
Gynecological examination every 12 months 
Densitometry  every 12-24  months in patients with HT 
Body weight assessment BMI 20-25 recommended 
Additional imaging and 
laboratory studies Only due to medical reasons 
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family physicians 5 years after treatment, and in patients with 
low-stage breast cancer (tumor diameter < 5 cm, fewer than 4 
affected lymph nodes) 1 year after treatment (11). Studies car-
ried out in different countries have shown that the efficacy of 
follow-up is comparable if performed by oncologists or family 
physicians (27-29). But can the Polish healthcare system adopt 
such solutions? Currently, the answer is no.
and predictive factors are sought out, which could identify pa-
tients at an increased risk of recurrence. To date, 11 genes that 
increase the risk of recurrence are known, but practical use of 
this information is limited (25,26).  
Lastly, it should be mentioned that international recommenda-
tions allow that follow-up assessments be carried out by trained 
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